Table 5.

Clinicopathologic Characteristics, Initial Risk Stratification, and Response to Therapy Reclassification in the Five Patients Classified as MSKCC-PDTC but Non-PDTC by Turin Proposal, and Lacking DM at Presentation, EVI, and GET

			Classification by Turin proposal
#	Age	Sex	Primary tumor	Lymph node metastasis	Tumor size (cm)	Margin status	Total number of lymph nodes with metastasis	Size of the largest lymph node (cm)	Mode of death	Time to death (years)	Site of DM	ATA 2015 risk stratification	Response to treatment
1	58	M	PTC, microcarcinomaa	Follicular variant PTC	0.4	Negative	2	3.2	Distant	8.4	Lung, bone, retroperitoneum	High risk	Biochemical incomplete response
2	82	F	Tall-cell variant PTC	Tall-cell variant PTC	4.1	Positive	4	1.2	Distant	1.4	Lung	Intermediate risk	Structural incomplete response
3	70	F	Tall-cell variant PTC	Tall-cell variant PTC	1.8	Positive	8	0.6	Distant	11.3	Lung	Intermediate risk	Excellent response
4	78	F	Columnar variant PTC	NA	2.5	Negative	NA	NA	Distant	3.1	Lung	Intermediate risk	Structural incomplete response
5	72	F	Classical variant PTC	Classical variant PTC	2	Negative	3	0.6	Unknown	11.9	Lung	Low risk	Excellent response

^aThis is the patient shown in Figure 2.

ATA, American Thyroid Association.